Hologic Looks To Clinical Reports To Support Reimbursement Hike For 3D Mammo
This article was originally published in The Gray Sheet
Executive Summary
Hologic is pressing forward with efforts to increase reimbursement for its recently launched Selenia Dimensions three-dimensional digital mammography system, but says it is unlikely to reach that goal until the results of several clinical studies are presented in late 2011 and early 2012.
You may also be interested in...
The Evolving World Of Breast Cancer Management
The device industry is playing a pivotal role in the evolution toward a more personalized approach to breast cancer management, with ongoing advances in minimally invasive treatment systems, tumor characterization and breast imaging technologies adding to the momentum. In the years ahead, as the breast cancer toolbox expands, the watchword will be “choice,” with physicians and patients offered more treatment options, targeted to their specific needs and desires, than ever before.
New Products In Brief
Boston Scientific’s next-generation ICDs; Covidien’s SpiderFX embolic protection device; Abbott’s vitamin D assay. More new products.
Hologic’s 3-D Mammo: Reimbursement Timing Uncertain Following Approval
Hologic says it is impossible to predict how long it will take to secure reimbursement for its newly approved Selenia Dimensions three-dimensional digital mammography system.